ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,437Medicare Part D Prescriptions Filled, Including Refills

Rank: 445 out of 1121

$386K Total Retail Price of All Prescriptions

Rank: 549 out of 1121

410 Patients Receiving at Least One Drug in Part D
72%Patients 65 Years and Older
67% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Tennessee
Lower avg

Schedule Two
Controlled Substances

5% of this provider’s 410 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

19% of this provider’s 410 patients filled at least one prescription for a schedule three drug, compared to an average of 15%.

Risky Drugs to Seniors

3% of this provider’s 5,979 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

20% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$46 was the average price of a prescription from this provider, compared to $55 among peers.

Prescriptions per Patient

21 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Tennessee
AMLODIPINE BESYLATE 395 306 1 5
HYDROCODONE-ACETAMINOPHEN 366 232 S3 2 3
SIMVASTATIN 340 270 3 1
METFORMIN HCL 229 176 4 8
FUROSEMIDE 217 158 5 7
LISINOPRIL 193 150 6 4
DONEPEZIL HCL 188 171 7 35
OMEPRAZOLE 184 137 8 6
CITALOPRAM HBR 167 128 9 18
ATENOLOL 146 99 10 16
METOPROLOL TARTRATE 134 78 11 9
TRIAMTERENE-HCTZ 124 85 12 38
TRAZODONE HCL 118 53 13 40
ZOLPIDEM TARTRATE 112 85 14 19
TAMSULOSIN HCL 109 109 15 32
MEGESTROL ACETATE 102 79 R 16 185
GABAPENTIN 95 65 17 13
CARVEDILOL 88 74 18 20
CLONIDINE HCL 87 58 19 39
BENAZEPRIL HCL 86 57 20 41
PREDNISONE 85 57 21 43
CEPHALEXIN 84 74 22 111
ALLOPURINOL 77 61 23 30
HYDROCHLOROTHIAZIDE 76 50 24 10
NOVOLIN R 73 35 25 174
DIVALPROEX SODIUM 71 52 26 98
ATORVASTATIN CALCIUM 70 50 27 15
NAMENDA 69 56 28 53
CIPROFLOXACIN HCL 68 46 29 57
GLIMEPIRIDE 67 60 30 34
RISPERIDONE 65 31 31 82
LISINOPRIL-HYDROCHLOROTHIAZIDE 64 41 32 31
LOSARTAN POTASSIUM 63 59 33 17
TRAMADOL HCL 62 42 34 25
HALOPERIDOL 62 37 34 242
RANITIDINE HCL 62 39 34 33
LEVOTHYROXINE SODIUM 62 37 34 2
WARFARIN SODIUM 62 39 34 11
MIRTAZAPINE 61 37 39 56
QUETIAPINE FUMARATE 60 24 40 75
AMITRIPTYLINE HCL 58 19 R 41 61
GLIPIZIDE 55 47 42 84
POTASSIUM CHLORIDE 55 38 42 12
NEXIUM 52 44 44 24
LANTUS 52 25 44 52
BENZTROPINE MESYLATE 50 29 R 46 224
DICLOFENAC SODIUM 50 41 46 112
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Oct. 25, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.